Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$95.40 -0.5%	$111.75	$76.53 ▼ $131.49	$22.89B	0.3	785,632 shs	722,296 shs
GSK GSK	$38.54 +0.6%	$37.11	$31.72 ▼ $45.93	$79.77B	0.58	4.34 million shs	2.25 million shs
JNJ Johnson & Johnson	$163.22 +0.9%	$158.35	$140.68 ▼ $169.99	$389.72B	0.47	7.05 million shs	6.75 million shs
MRNA Moderna	$32.12 +2.0%	$34.78	$29.25 ▼ $170.47	$12.42B	1.86	6.65 million shs	6.19 million shs
NVAX Novavax	$7.26 -1.8%	$8.16	$3.81 ▼ $23.86	$1.17B	2.92	7.95 million shs	2.60 million shs
PFE Pfizer	$25.05 -0.6%	$26.09	$24.48 ▼ $31.54	$142.08B	0.61	36.67 million shs	51.26 million shs
SRPT Sarepta Therapeutics	$71.81 -1.5%	$103.61	$70.91 ▼ $173.25	$7.07B	0.79	1.23 million shs	1.36 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	-0.52%	-0.86%	-14.05%	-16.28%	+2.61%
GSK GSK	+0.67%	-2.27%	+0.40%	+13.09%	-10.36%
JNJ Johnson & Johnson	+0.97%	+0.18%	-1.75%	+12.52%	+3.33%
MRNA Moderna	+2.03%	-1.02%	-3.30%	-19.96%	-70.96%
NVAX Novavax	-1.76%	-5.96%	+1.26%	-12.32%	+49.69%
PFE Pfizer	-0.56%	-4.26%	-6.37%	-5.89%	-9.79%
SRPT Sarepta Therapeutics	-1.47%	-2.23%	-32.86%	-40.90%	-44.86%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTX BioNTech	2.4379 of 5 stars	4.4	2.0	0.0	0.0	2.1	0.8	0.0
GSK GSK	2.8958 of 5 stars	2.3	5.0	2.5	0.0	3.0	0.0	1.3
JNJ Johnson & Johnson	4.4388 of 5 stars	2.3	3.0	4.2	3.9	3.5	2.5	0.6
MRNA Moderna	4.1976 of 5 stars	4.0	1.0	0.0	4.6	1.9	2.5	0.6
NVAX Novavax	3.992 of 5 stars	3.2	2.0	0.0	4.7	2.7	1.7	0.6
PFE Pfizer	4.9874 of 5 stars	3.3	3.0	4.2	4.2	3.3	3.3	3.1
SRPT Sarepta Therapeutics	4.8422 of 5 stars	4.4	3.0	0.0	4.2	2.9	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.89	Moderate Buy	$143.73	50.66% Upside
GSK GSK	2.60	Moderate Buy	$43.25	12.22% Upside
JNJ Johnson & Johnson	2.56	Moderate Buy	$171.33	4.97% Upside
MRNA Moderna	2.04	Hold	$59.00	83.69% Upside
NVAX Novavax	2.43	Hold	$18.00	147.93% Upside
PFE Pfizer	2.63	Moderate Buy	$31.92	27.43% Upside
SRPT Sarepta Therapeutics	2.83	Moderate Buy	$167.41	133.13% Upside

Current Analyst Ratings Breakdown

Latest PFE, BNTX, MRNA, JNJ, NVAX, SRPT, and GSK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/21/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$40.00 ➝ $33.00
3/20/2025	SRPT Sarepta Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$105.00 ➝ $80.00
3/19/2025	SRPT Sarepta Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$124.00 ➝ $99.00
3/19/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell ➝ Sell	$75.00 ➝ $75.00
3/18/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/18/2025	SRPT Sarepta Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$202.00 ➝ $202.00
3/18/2025	SRPT Sarepta Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$163.00 ➝ $163.00
3/13/2025	BNTX BioNTech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$145.00
3/13/2025	MRNA Moderna	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$40.00
3/12/2025	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
3/11/2025	BNTX BioNTech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$145.00 ➝ $139.00

(Data available from 3/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$2.75B	8.32	$4.10 per share	23.25	$92.17 per share	1.04
GSK GSK	$31.38B	2.54	$6.10 per share	6.32	$8.07 per share	4.78
JNJ Johnson & Johnson	$88.82B	4.43	$13.41 per share	12.17	$29.69 per share	5.50
MRNA Moderna	$3.20B	3.88	N/A	N/A	$28.33 per share	1.13
NVAX Novavax	$682.16M	1.71	N/A	N/A	($6.04) per share	-1.20
PFE Pfizer	$63.63B	2.23	$3.93 per share	6.38	$15.81 per share	1.58
SRPT Sarepta Therapeutics	$1.90B	3.66	N/A	N/A	$9.19 per share	7.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	$1.01B	-$3.00	N/A	N/A	N/A	-15.16%	-2.35%	-2.05%	5/5/2025 (Estimated)
GSK GSK	$3.29B	$1.59	24.24	8.29	1.12	8.13%	48.59%	11.11%	4/30/2025 (Estimated)
JNJ Johnson & Johnson	$14.07B	$6.65	24.54	14.74	2.56	18.20%	34.24%	13.63%	4/15/2025 (Estimated)
MRNA Moderna	-$3.56B	-$9.28	N/A	N/A	N/A	-110.04%	-28.74%	-21.83%	5/1/2025 (Estimated)
NVAX Novavax	-$545.06M	-$1.33	N/A	90.75	2.85	-32.18%	N/A	-17.05%	5/9/2025 (Estimated)
PFE Pfizer	$8.03B	$1.41	17.77	8.27	0.64	12.62%	19.47%	8.09%	4/29/2025 (Estimated)
SRPT Sarepta Therapeutics	-$535.98M	$2.28	57.45	6.56	N/A	7.43%	11.00%	3.35%	4/29/2025 (Estimated)

Latest PFE, BNTX, MRNA, JNJ, NVAX, SRPT, and GSK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/15/2025	N/A	JNJ Johnson & Johnson	$2.59	N/A	N/A	N/A	$21.65 billion	N/A
3/10/2025	Q4 24	BNTX BioNTech	$0.38	$1.08	+$0.70	$1.15	$1.24 billion	$1.19 billion
2/27/2025	Q4 24	NVAX Novavax	-$0.75	-$0.51	+$0.24	-$0.51	$85.48 million	$88.31 million
2/5/2025	Q4 2024	GSK GSK	$0.44	$0.59	+$0.15	$0.26	$7.75 billion	N/A
2/4/2025	Q4 2024	PFE Pfizer	$0.48	$0.63	+$0.15	$0.07	$17.26 billion	$17.76 billion
1/22/2025	Q4 2024	JNJ Johnson & Johnson	$1.99	$2.04	+$0.05	$1.41	$22.44 billion	$22.52 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	$1.53	1.60%	N/A	N/A	N/A
GSK GSK	$1.57	4.07%	-17.33%	98.74%	N/A
JNJ Johnson & Johnson	$4.96	3.04%	+5.43%	74.59%	63 Years
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.87%	+2.50%	121.99%	16 Years
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest PFE, BNTX, MRNA, JNJ, NVAX, SRPT, and GSK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/5/2025	GSK GSK	quarterly	$0.3932	4.2%	2/21/2025	2/21/2025	4/10/2025
1/2/2025	JNJ Johnson & Johnson	quarterly	$1.24	3.43%	2/18/2025	2/18/2025	3/4/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	7.33	7.21
GSK GSK	1.12	0.78	0.52
JNJ Johnson & Johnson	0.43	1.11	0.86
MRNA Moderna	N/A	3.67	3.62
NVAX Novavax	N/A	0.93	0.93
PFE Pfizer	0.63	1.00	0.73
SRPT Sarepta Therapeutics	0.93	3.84	3.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
GSK GSK	15.74%
JNJ Johnson & Johnson	69.55%
MRNA Moderna	75.33%
NVAX Novavax	53.04%
PFE Pfizer	68.36%
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
GSK GSK	10.00%
JNJ Johnson & Johnson	0.16%
MRNA Moderna	11.00%
NVAX Novavax	1.00%
PFE Pfizer	0.06%
SRPT Sarepta Therapeutics	7.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	3,080	239.97 million	193.71 million	Optionable
GSK GSK	90,100	2.07 billion	1.87 billion	Optionable
JNJ Johnson & Johnson	152,700	2.41 billion	2.40 billion	Optionable
MRNA Moderna	3,900	386.62 million	324.40 million	Optionable
NVAX Novavax	1,990	160.84 million	158.58 million	Optionable
PFE Pfizer	83,000	5.67 billion	5.66 billion	Optionable
SRPT Sarepta Therapeutics	1,314	97.03 million	88.17 million	Optionable

PFE, BNTX, MRNA, JNJ, NVAX, SRPT, and GSK Headlines

Recent News About These Companies

Corient Private Wealth LLC Invests $786,000 in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

March 28 at 3:51 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

March 27 at 10:00 AM | accessnewswire.com

Corebridge Financial Inc. Has $13.26 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

March 27 at 4:49 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

March 26 at 8:00 PM | globenewswire.com

Sarepta Therapeutics (NASDAQ:SRPT) Hits New 52-Week Low - What's Next?

March 26 at 5:12 PM | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Stockholders to Inquire about Securities Investigation

March 26 at 10:00 AM | accessnewswire.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Bought by Teacher Retirement System of Texas

March 26 at 4:02 AM | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Investors to Learn More About the Investigation

March 25 at 10:00 AM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

March 25 at 10:00 AM | prnewswire.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Holdings Lifted by Emerald Advisers LLC

March 25 at 5:37 AM | marketbeat.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Position Reduced by Signaturefd LLC

March 25 at 3:53 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

March 24, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Stockholders to Connect

March 24, 2025 | accessnewswire.com

How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion

March 24, 2025 | zacks.com

Simplify Asset Management Inc. Cuts Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

March 24, 2025 | marketbeat.com

StockWatch: After DMD Patient Death, Analysts Still Bullish on Sarepta

March 23, 2025 | genengnews.com

Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

March 23, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT

March 23, 2025 | accessnewswire.com

Is This Stock a Buy After a Massive 20% Drop in 1 Day?

March 23, 2025 | fool.com

Scotiabank Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $80.00

March 23, 2025 | americanbankingnews.com

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 4% After Analyst Downgrade

March 22, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
By Thomas Hughes | March 12, 2025
View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
AST SpaceMobile Stock Surges 17% After Analyst Upgrade
By Nathan Reiff | February 26, 2025
View AST SpaceMobile Stock Surges 17% After Analyst Upgrade
Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
By Jea Yu | March 11, 2025
View Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares
Resilient Investing: 3 Stocks Built to Weather Market Volatility
By Jeffrey Neal Johnson | March 17, 2025
View Resilient Investing: 3 Stocks Built to Weather Market Volatility

PFE, BNTX, MRNA, JNJ, NVAX, SRPT, and GSK Company Descriptions

BioNTech NASDAQ:BNTX

$95.40 -0.50 (-0.52%)

Closing price 03/27/2025 04:00 PM Eastern

Extended Trading

$95.48 +0.08 (+0.08%)

As of 08:09 AM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

GSK NYSE:GSK

$38.54 +0.23 (+0.60%)

Closing price 03/27/2025 03:59 PM Eastern

Extended Trading

$38.70 +0.16 (+0.43%)

As of 08:11 AM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Johnson & Johnson NYSE:JNJ

$163.22 +1.50 (+0.93%)

Closing price 03/27/2025 03:59 PM Eastern

Extended Trading

$163.88 +0.66 (+0.40%)

As of 08:25 AM Eastern

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Moderna NASDAQ:MRNA

$32.12 +0.64 (+2.03%)

Closing price 03/27/2025 04:00 PM Eastern

Extended Trading

$31.98 -0.14 (-0.45%)

As of 08:26 AM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Novavax NASDAQ:NVAX

$7.26 -0.13 (-1.76%)

Closing price 03/27/2025 04:00 PM Eastern

Extended Trading

$7.25 -0.01 (-0.14%)

As of 08:26 AM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Pfizer NYSE:PFE

$25.05 -0.16 (-0.63%)

Closing price 03/27/2025 03:59 PM Eastern

Extended Trading

$25.02 -0.03 (-0.12%)

As of 08:28 AM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Sarepta Therapeutics NASDAQ:SRPT

$71.81 -1.07 (-1.47%)

Closing price 03/27/2025 04:00 PM Eastern

Extended Trading

$72.06 +0.25 (+0.34%)

As of 08:23 AM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PFE, BNTX, MRNA, JNJ, NVAX, SRPT, and GSK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PFE, BNTX, MRNA, JNJ, NVAX, SRPT, and GSK Earnings

Compare Dividends

Latest PFE, BNTX, MRNA, JNJ, NVAX, SRPT, and GSK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PFE, BNTX, MRNA, JNJ, NVAX, SRPT, and GSK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

PFE, BNTX, MRNA, JNJ, NVAX, SRPT, and GSK Company Descriptions

BioNTech NASDAQ:BNTX

GSK NYSE:GSK

Johnson & Johnson NYSE:JNJ

Moderna NASDAQ:MRNA

Novavax NASDAQ:NVAX

Pfizer NYSE:PFE

Sarepta Therapeutics NASDAQ:SRPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools